Exhibit 99.1 CureVac N.V. Unaudited Interim Condensed Consolidated Financial Statements As of March 31, 2024 and December 31, 2023 and for the three months ended March 31, 2024 and 2023 CureVac N.V. Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) Three months ended March 31, Note 2023 2024 (in thousands of EUR, except per share amounts) (unaudited) Revenue 3.1 7,129 12,373 Cost of sales 3.2 (20,634) (41,690) Selling and distribution expenses 3.3 (824) (955) Rese ...